The regulatory downgrade significantly increases binary risk around the August 2026 data readout. Traders should monitor for any additional FDA communications and prepare for high volatility upon results. Without a validated endpoint, the path to approval is uncertain.
Price Chart
Executive Summary
Longeveron disclosed that the FDA rejected the primary endpoint (RVEF) of its Phase 2b ELPIS II trial for HLHS, and the FDA no longer considers the trial 'pivotal.' Top-line results are still expected in August 2026. This is a material regulatory setback for a micro-cap biotech with no approved products.
Key Facts
- FDA stated primary endpoint (RVEF) is not appropriate to demonstrate efficacy
- FDA no longer refers to ELPIS II as a pivotal trial
- FDA willing to discuss results after trial completion
- Top-line results expected August 2026
- Company intends to submit a Sponsor Statistical Analysis Plan with composite endpoint
Financial Impact
No financial figures provided; market cap ~$20M
Risk Factors
- Failed or inconclusive top-line results could render the program worthless
- No agreed-upon primary endpoint may delay or prevent BLA filing
- Potential need for additional costly trials or capital raise
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-053902 |
| Document: ea028985301ex99-1.htm | 0001213900-26-053902 |
| Document: 0001213900-26-053902-index-headers.html | 0001213900-26-053902 |
| Document: 0001213900-26-053902-index.html | 0001213900-26-053902 |
| Document: 0001213900-26-053902.txt | 0001213900-26-053902 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 17d ago | 8-K | $6.86 $2.49 | ▼ −63.70% | ▼ −64.52% | $2.57 (−62.61%) |
Jul 13, 2026 11w ago | 3 | $0.6223 $0.6022 | ▼ −3.23% | ▼ −1.93% | $2.57 (+312.18%) |
Jun 5, 2026 16w ago | 8-K | $0.7540 $0.7900 | ▲ +4.77% | ▲ +2.66% | $2.57 (+240.19%) |
May 20, 2026 19w ago | Press Release | $0.7210 $0.8150 | ▲ +13.04% | ▲ +11.44% | $2.57 (+255.76%) |
May 13, 2026 20w ago | 8-K | $0.7030 $0.7210 | ▲ +2.56% | ▲ +3.28% | $2.57 (+264.86%) |
May 8, 2026 20w ago | 8-K | $0.8380 $0.6760 | ▲ +19.33% | ▲ +19.25% | $2.57 (−206.09%) |
Apr 20, 2026 23w ago | EFFECT | $1.04 $0.9000 | ▲ +13.46% | ▲ +14.37% | $2.57 (−146.63%) |
Apr 10, 2026 24w ago | 8-K | $1.12 $1.04 | ▼ −7.14% | ▼ −10.44% | $2.57 (+129.02%) |
Apr 10, 2026 24w ago | S-1 | $1.12 $1.04 | ▲ +7.14% | ▲ +10.44% | $2.57 (−129.02%) |
Mar 17, 2026 28w ago | Press Release | $0.9760 $0.9730 | ▲ +0.31% | ▼ −0.41% | $2.57 (−162.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access